These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35960655)

  • 1. Development of an Orally Active Small-Molecule Inhibitor of Receptor Activator of Nuclear Factor-κB Ligand.
    Yang K; Li S; Wang T; Yan X; He Q; Ning R; Xu X; Yao W; Zhang X; Yang C; Jiang M; Deng L
    J Med Chem; 2022 Aug; 65(16):10992-11009. PubMed ID: 35960655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Small-Molecules Targeting Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-Receptor Activator of Nuclear Factor-κB (RANK) Protein-Protein Interaction by Structure-Based Virtual Screening and Hit Optimization.
    Jiang M; Peng L; Yang K; Wang T; Yan X; Jiang T; Xu J; Qi J; Zhou H; Qian N; Zhou Q; Chen B; Xu X; Deng L; Yang C
    J Med Chem; 2019 Jun; 62(11):5370-5381. PubMed ID: 31082234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (-)-Epicatechin 3-O-β-D-allopyranoside prevent ovariectomy-induced bone loss in mice by suppressing RANKL-induced NF-κB and NFATc-1 signaling pathways.
    Hsiao HB; Wu JB; Lin WC
    BMC Complement Altern Med; 2017 May; 17(1):245. PubMed ID: 28468652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways.
    Chen K; Yan Z; Wang Y; Yang Y; Cai M; Huang C; Li B; Yang M; Zhou X; Wei X; Yang C; Chen Z; Zhai X; Li M
    Biomed Pharmacother; 2020 Jun; 126():110067. PubMed ID: 32272431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF-κB activation and down regulating inflammatory cytokines.
    Naidu VG; Dinesh Babu KR; Thwin MM; Satish RL; Kumar PV; Gopalakrishnakone P
    Chem Biol Interact; 2013 Apr; 203(2):467-79. PubMed ID: 23333834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Butein, a tetrahydroxychalcone, suppresses cancer-induced osteoclastogenesis through inhibition of receptor activator of nuclear factor-kappaB ligand signaling.
    Sung B; Cho SG; Liu M; Aggarwal BB
    Int J Cancer; 2011 Nov; 129(9):2062-72. PubMed ID: 21170936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RANKL signaling and osteoclastogenesis is negatively regulated by cardamonin.
    Sung B; Prasad S; Yadav VR; Gupta SC; Reuter S; Yamamoto N; Murakami A; Aggarwal BB
    PLoS One; 2013; 8(5):e64118. PubMed ID: 23691159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guggulsterone inhibits osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand and by tumor cells by suppressing nuclear factor-kappaB activation.
    Ichikawa H; Aggarwal BB
    Clin Cancer Res; 2006 Jan; 12(2):662-8. PubMed ID: 16428513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cumambrin A prevents OVX-induced osteoporosis
    Zhou L; Liu Q; Hong G; Song F; Zhao J; Yuan J; Xu J; Tan RX; Tickner J; Gu Q; Xu J
    FASEB J; 2019 Jun; 33(6):6726-6735. PubMed ID: 30807230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-RANKL antibody].
    Omiya T; Tanaka S
    Nihon Rinsho; 2015 Oct; 73(10):1690-5. PubMed ID: 26529931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RANKL stimulates inducible nitric-oxide synthase expression and nitric oxide production in developing osteoclasts. An autocrine negative feedback mechanism triggered by RANKL-induced interferon-beta via NF-kappaB that restrains osteoclastogenesis and bone resorption.
    Zheng H; Yu X; Collin-Osdoby P; Osdoby P
    J Biol Chem; 2006 Jun; 281(23):15809-20. PubMed ID: 16613848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (2S)-2'-Methoxykurarinone inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling.
    Kim JY; Kim JY; Kim JJ; Oh J; Kim YC; Lee MS
    Biol Pharm Bull; 2014; 37(2):255-61. PubMed ID: 24492722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triptolide, a diterpene, inhibits osteoclastogenesis, induced by RANKL signaling and human cancer cells.
    Park B
    Biochimie; 2014 Oct; 105():129-36. PubMed ID: 25047443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sanguiin H-6, a constituent of Rubus parvifolius L., inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis and bone resorption in vitro and prevents tumor necrosis factor-α-induced osteoclast formation in vivo.
    Sakai E; Aoki Y; Yoshimatsu M; Nishishita K; Iwatake M; Fukuma Y; Okamoto K; Tanaka T; Tsukuba T
    Phytomedicine; 2016 Jul; 23(8):828-37. PubMed ID: 27288918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative NF-κB Regulates RANKL-Induced Osteoclast Differentiation and Mitochondrial Biogenesis via Independent Mechanisms.
    Zeng R; Faccio R; Novack DV
    J Bone Miner Res; 2015 Dec; 30(12):2287-99. PubMed ID: 26094846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
    Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
    Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production.
    Lee SY; Lee KS; Yi SH; Kook SH; Lee JC
    PLoS One; 2013; 8(12):e80873. PubMed ID: 24324641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
    Chen T; Feng X
    Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.